Jianpi Shengxue Tablet Improves Iron Metabolism and Nutritional Status in Renal Anemia, reports a Multicenter Clinical Study

This multicenter, randomized, open, parallel-controlled clinical study evaluated the effectiveness of the Jianpi Shengxue tablet in treating renal anemia. 
A total of 200 patients with renal anemia were enrolled between December 2020 and December 2022 and randomly assigned to either a control group treated with a polysaccharide-iron complex or an experimental group receiving Jianpi Shengxue tablets. After 8 weeks of continuous treatment, outcomes related to anemia and iron metabolism were compared between the two groups.
Results indicated that the experimental group showed significant improvements in red blood cell count (RBC), hematocrit (HCT), reticulocyte percentage (RET), serum ferritin (SF), serum iron (SI), transferrin saturation (TSAT), and serum albumin (ALB), while clinical symptom scores and total iron binding capacity decreased (P<0.01). 
Notably, improvements in RBC, HCT, RET, SF, SI, TSAT, ALB, and clinical symptoms such as fatigue, anorexia, dull skin complexion, and numbness were significantly greater in the experimental group compared to the control group (P<0.05). The overall effectiveness rate of Jianpi Shengxue tablets was significantly higher than that of the control treatment (P<0.01).
These findings demonstrate that Jianpi Shengxue tablets are effective in managing renal anemia, significantly enhancing iron metabolism, nutritional status, and clinical symptoms, offering a promising alternative for anemia treatment in patients with kidney disease.